This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2i4x

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2i4x.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2i4x.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2i4x| PDB=2i4x | SCENE= }}
{{STRUCTURE_2i4x| PDB=2i4x | SCENE= }}
-
'''HIV-1 Protease I84V, L90M with GS-8374'''
+
===HIV-1 Protease I84V, L90M with GS-8374===
-
==Overview==
+
<!--
-
The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clinical outcome and control of HIV-1 infection. However, cross-resistance among PIs due to a wide spectrum of mutations in viral protease is a major factor limiting their broader clinical use. Here we report on the suppression of PI resistance using a covalent attachment of a phosphonic acid motif to a peptidomimetic inhibitor scaffold. The resulting phosphonate analogs maintain high binding affinity to HIV-1 protease, potent antiretroviral activity, and unlike the parent molecules, display no loss of potency against a panel of clinically important PI-resistant HIV-1 strains. As shown by crystallographic analysis, the phosphonate moiety is highly exposed to solvent with no discernable interactions with any of the enzyme active site or surface residues. We term this effect "solvent anchoring" and demonstrate that it is driven by a favorable change in the inhibitor binding entropy upon the interaction with mutant enzymes. This type of thermodynamic behavior, which was not found with the parent scaffold fully buried in the enzyme active site, is a result of the increased degeneracy of inhibitor binding states, allowing effective molecular adaptation to the expanded cavity volume of mutant proteases. This strategy, which is applicable to various PI scaffolds, should facilitate the design of novel PIs and potentially other antiviral therapeutics.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16979654}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16979654 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16979654}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Hiv-1 protease i84vl90m inhibitor]]
[[Category: Hiv-1 protease i84vl90m inhibitor]]
[[Category: Hydrolase]]
[[Category: Hydrolase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 07:04:31 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 23:24:18 2008''

Revision as of 20:24, 27 July 2008

Image:2i4x.png

Template:STRUCTURE 2i4x

HIV-1 Protease I84V, L90M with GS-8374

Template:ABSTRACT PUBMED 16979654

About this Structure

2I4X is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring., Cihlar T, He GX, Liu X, Chen JM, Hatada M, Swaminathan S, McDermott MJ, Yang ZY, Mulato AS, Chen X, Leavitt SA, Stray KM, Lee WA, J Mol Biol. 2006 Oct 27;363(3):635-47. Epub 2006 Aug 2. PMID:16979654

Page seeded by OCA on Sun Jul 27 23:24:18 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2i4x"
Personal tools